PT-141 vs Sildenafil (Viagra)
PT-141 (bremelanotide/Vyleesi) and sildenafil (Viagra) are both used for sexual dysfunction, but they act through fundamentally different pathways. Sildenafil enhances peripheral vasodilation via PDE5 inhibition, while PT-141 activates central melanocortin circuits to generate pro-sexual signaling. This mechanistic divergence produces distinct efficacy profiles, side effects, and clinical applications.
Mechanism of Action
Section titled “Mechanism of Action”Sildenafil: PDE5 Inhibition
Section titled “Sildenafil: PDE5 Inhibition”Sildenafil is a selective phosphodiesterase type 5 (PDE5) inhibitor. During sexual stimulation, nitric oxide (NO) is released from non-adrenergic non-cholinergic (NANC) neurons and endothelial cells, activating guanylyl cyclase to produce cyclic guanosine monophosphate (cGMP). cGMP mediates smooth muscle relaxation in the corpus cavernosum, producing erection. PDE5 degrades cGMP, terminating the signal.
Sildenafil inhibits PDE5 with IC₅₀ of ~3.7 nM, preventing cGMP breakdown and amplifying the NO-cGMP relaxation response. Critically, sildenafil requires sexual stimulation to work — it does not produce erection in the absence of neural NO release.
PT-141: Melanocortin Pathway
Section titled “PT-141: Melanocortin Pathway”PT-141 is a synthetic cyclic heptapeptide analog of α-melanocyte-stimulating hormone (α-MSH). It acts as a selective agonist at the melanocortin-4 receptor (MC4R) in the hypothalamus, particularly the paraventricular nucleus and medial preoptic area.
MC4R activation triggers pro-sexual signaling via oxytocinergic and dopaminergic pathways in the medial preoptic area (MPOA) and paraventricular nucleus (PVN). This central mechanism generates sexual arousal independently of peripheral vascular function, making PT-141 effective in contexts where PDE5 inhibitors fail (e.g., antidepressant-induced sexual dysfunction, spinal cord injury).
Comparison Table
Section titled “Comparison Table”| Property | PT-141 (Bremelanotide) | Sildenafil (Viagra) |
|---|---|---|
| Drug class | Melanocortin agonist | PDE5 inhibitor |
| Mechanism | MC4R agonism (central) | PDE5 inhibition (peripheral) |
| Target | Hypothalamus (MPOA, PVN) | Corpus cavernosum |
| Requires stimulation | No | Yes |
| Onset | 30–60 min (SC) | 30–60 min (oral) |
| Duration | ~6–8 hrs | ~4–6 hrs |
| Route | Subcutaneous | Oral |
| Approval | Female sexual dysfunction | Erectile dysfunction |
Pharmacokinetics
Section titled “Pharmacokinetics”Sildenafil
Section titled “Sildenafil”- Oral bioavailability: ~40%
- Tmax: 30–120 minutes
- Plasma half-life: 3–5 hours
- Metabolism: CYP3A4 (major), CYP2C9 (minor)
- Active metabolite: N-desmethylsildenafil (43% potency of parent)
- Food interaction: High-fat meals delay Tmax by ~1 hour
PT-141
Section titled “PT-141”- Subcutaneous bioavailability: ~100%
- Tmax: ~30–60 minutes (SC)
- Plasma half-life: ~2.7 hours
- Metabolism: CYP3A4 and renal elimination
- No active metabolites
- Dose: 1.75 mg SC PRN (max 1 dose/day, 8 doses/month)
Efficacy in Erectile Dysfunction
Section titled “Efficacy in Erectile Dysfunction”Sildenafil
Section titled “Sildenafil”Sildenafil has robust clinical evidence in male erectile dysfunction (ED):
- Hardness score improvement: 60–70% of attempts result in erection sufficient for intercourse (vs. ~20% with placebo)
- IIEF-EF domain improvement: Mean increase of 5.7–8.2 points
- Dose-response: 50 mg (standard), 100 mg (maximum effective), 25 mg (starting dose)
- Success rate across etiologies: Effective in vasculogenic, psychogenic, and post-prostatectomy ED (with nerve-sparing)
- Combination therapy: Works with intracavernosal injections for refractory cases
PT-141 in Male ED
Section titled “PT-141 in Male ED”PT-141’s efficacy in male ED is more modest:
- Phase 2 trials: Statistically significant improvement in erectile function in a subset of men, particularly those with PDE5 inhibitor failure
- Response rate: ~30–40% of PDE5 non-responders achieved improved erectile function
- Not FDA-approved for male ED: Approved only for female sexual dysfunction
- Mechanism advantage: May benefit men with neurogenic ED (spinal cord injury, post-surgery)
Efficacy in Female Sexual Dysfunction
Section titled “Efficacy in Female Sexual Dysfunction”Sildenafil
Section titled “Sildenafil”Sildenafil has been studied extensively in female sexual arousal disorder (FSAD):
- Systematic reviews: Modest improvement in subjective arousal, no consistent improvement in physiological arousal
- Pre-menopausal women: Minimal benefit in most trials
- Post-menopausal women: Small benefit in some studies, but not clinically meaningful
- Not approved for female sexual dysfunction
PT-141
Section titled “PT-141”PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women:
- RECONNAISSANCE trials: Significant improvement in sexual desire (FSDS-R domain score improvement of 1.2–1.6 points vs. 0.5–0.8 placebo)
- Satisfying sexual events: Increase from baseline by 1.2–1.5 events/month vs. 0.6–0.8 placebo
- Dysfunction type: Most effective for desire/arousal dysfunction, not orgasmic dysfunction
- Response rate: ~40–50% of women achieve clinically meaningful improvement
Side Effect Profiles
Section titled “Side Effect Profiles”Sildenafil
Section titled “Sildenafil”| Side Effect | Incidence | Mechanism |
|---|---|---|
| Headache | 16% | PDE5 inhibition in cerebral vessels |
| Flushing | 10% | Peripheral vasodilation |
| Dyspepsia | 7% | PDE5 in GI smooth muscle |
| Nasal congestion | 4% | Nasal mucosal vasodilation |
| Visual disturbances (cyanopsia) | 3% | PDE6 inhibition in retina |
| Priapism | <0.1% | Excessive vasodilation |
| Hypotension | Rare | Additive with nitrates |
Contraindications: Nitrates (absolute), alpha-blockers (relative), recent stroke/MI, retinitis pigmentosa
PT-141
Section titled “PT-141”| Side Effect | Incidence | Mechanism |
|---|---|---|
| Nausea | 13–18% | Central MC4R activation (chemoreceptor trigger zone) |
| Flushing | 6–8% | Melanocortin-mediated vasodilation |
| Headache | 6–10% | Central/peripheral effects |
| Injection site reactions | 3–5% | Local irritation |
| Hyperpigmentation | <1% | MSH receptor activation in melanocytes |
Contraindications: Uncontrolled hypertension, recent cardiovascular events, concurrent use with nitrates
Key Differences Summary
Section titled “Key Differences Summary”| Factor | PT-141 | Sildenafil |
|---|---|---|
| Primary indication | Female HSDD | Male ED |
| Mechanism | Central (MC4R) | Peripheral (PDE5) |
| Requires arousal | No | Yes |
| Oral option | No (SC only) | Yes |
| Nausea incidence | High (13–18%) | Low (<5%) |
| Visual effects | No | Yes (cyanopsia) |
| Male efficacy | Modest (PDE5-refractory) | Strong (first-line) |
| Female efficacy | Strong (approved) | Weak (not approved) |
When to Choose Which
Section titled “When to Choose Which”Sildenafil is preferred when:
- Male erectile dysfunction is the primary complaint
- Oral administration is preferred
- Peripheral vascular function is intact
- Patient can be counseled on timing relative to meals
- Cost or availability favors PDE5 inhibitors
PT-141 may be considered when:
- Female hypoactive sexual desire disorder is diagnosed
- PDE5 inhibitors have failed in male ED (off-label)
- Neurogenic ED is present (spinal cord injury, post-surgical)
- Central arousal mechanism is the therapeutic target
- Patient cannot tolerate PDE5 inhibitor side effects
References
Section titled “References”- Rosen RC, et al. “Oral sildenafil in the treatment of erectile dysfunction.” NEJM 1998;338:1397-1404.
- Clayton AH, et al. “Bremelanotide for hypoactive sexual desire disorder in premenopausal women.” J Clin Psychopharmacol 2019;39:261-267.
- Goldstein I, et al. “Oral sildenafil in the treatment of erectile dysfunction.” NEJM 1998;338:1397-1404.
- Simon JA, et al. “Bremelanotide for treatment of hypoactive sexual desire disorder.” Obstet Gynecol 2019;133:1023-1033.
- Shivers ML, et al. “PT-141 for erectile dysfunction.” J Urol 2004;171:2365-2369.